Timolol plus maximum tolerated antiglaucoma therapy: a one-year followup study.

Area of Science:

• Ophthalmology
• Glaucoma Research
• Pharmacology

Background:

• Primary open-angle glaucoma and ocular hypertension require effective intraocular pressure management.
• Maximally tolerated medical regimens are often used but may not achieve target pressures.
• Filtering surgery is an option when medical therapy fails.

Purpose of the Study:

• To evaluate the efficacy of adding topical timolol maleate to existing medical regimens for glaucoma patients.
• To assess the reduction in intraocular pressure and the need for surgery.

Main Methods:

• Thirty-three eyes of 22 patients with primary open-angle glaucoma or ocular hypertension were included.
• Topical timolol maleate was added to their maximally tolerated medical regimens.
• Patients were monitored for one year to assess intraocular pressure and treatment outcomes.

Main Results:

• 76% of eyes (25/33) were successfully managed with medication for one year.
• Only 24% of eyes (8/33) required subsequent filtering surgery.
• 39% of medically treated eyes achieved intraocular pressures of 21 mm Hg or less.
• 52% of eyes (17/33) showed a mean intraocular pressure decrease of 5 mm Hg or more after adding timolol.

Conclusions:

• Topical timolol maleate is an effective adjunctive therapy for managing primary open-angle glaucoma and ocular hypertension.
• Adding timolol maleate can reduce the need for glaucoma surgery in many patients.
• This treatment strategy offers a viable option for achieving target intraocular pressures with minimal side effects.